Huntington's Disease Society of America
Arvind Sreedharan
Arvind Sreedharan is a Director of Marketing in Movement Disorders at Lundbeck LLC, an international pharmaceutical company, focused on improving the quality of life of people suffering from psychiatric and neurological disorders. He has held numerous positions in sales, sales management, training and marketing in the pharma industry over the last 23 years. Over the last 4 plus years as Director of Marketing , Arvind has played an instrumental role in the launch and commercialization of Xenazine, the first FDA approved drug to treat a symptom of Huntington’s Disease. As a representative of Lundbeck, Arvind has been a strong strategic partner with HDSA national on numerous educational and fundraising initiatives to support the HD community. Arvind is an active participant at many local HDSA events in the Chicago area.
Arvind is a graduate of the University of North Carolina with a BA in Biology/History.